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Abstract
Background:Hypoglycaemia accounts for approximately one tenth of term
admissions to neonatal units, can cause long-term neurodevelopmental impairment
and is associated with significant burden to the affected infants, families and the
health system.
Objective: To define the prevalence, length and cost of admissions for
hypoglycaemia in infants born at greater than 35 weeks gestation and to identify
antenatal and perinatal predictors of those outcomes.
Material and Methods: This was a retrospective audit of infants admitted for
hypoglycaemia between 1/1/2012 and 31/12/2015, in a level three neonatal intensive
care unit at King’s College Hospital NHS Foundation Trust, London. The main
outcome measures were the prevalence, length and cost of admissions for
hypoglycaemia and antenatal and postnatal predictors of the length and cost of
stay.
Results: There were 474 admissions for hypoglycaemia (17.8% of total admissions).
Their median (IQR) blood glucose on admission was 2.1 (1.7-2.4) mmol/L, gestation
at delivery 38.1 (36.7-39.3) weeks, birthweight percentile 31.4 (5.4–68.9), their
length of stay was 3.0 (2.0-5.0). Admissions equated to a total of 2107 hospital
days. The total cost of stay was 1,316,591 GBP. The antenatal factors associated
with admission for hypoglycaemia were maternal hypertension (19.8%), maternal
diabetes (24.5%), FGR (25.9%) and pathological intrapartum cardiotocograph
(23.4%). In 13.7% of cases there was no associated pregnancy complication.
Multivariate logistic regression analysis demonstrated lower gestational age, z-score
birthweight squared, exclusive breastfeeding and maternal prescribed nifedipine
were independently associated with the length and cost of stay.
Conclusions: Hypoglycaemia accounted for approximately one fifth of admissions
after 35 weeks gestation. Lower gestational age and admission blood glucose, low
and high z-score birthweight, maternal nifedipine and exclusive breastfeeding are
associated with longer duration of stay.
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Short title: Neonatal admissions for hypoglycaemia >35 weeks
Key words: Hypoglycaemia, neonatal admissions, cost of stay, length of stay, fetal
growth restriction.
JU
ST
 AC
CE
PT
ED
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 08
:24
 27
 O
cto
be
r 2
01
7 
JU
ST
 AC
CE
PT
ED
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 08
:24
 27
 O
cto
be
r 2
01
7 
The aims of this study were to determine the prevalence of admissions for
hypoglycaemia in late preterm and term infants to a tertiary neonatal unit, to report
the length and cost of those admissions and identify independent antenatal and
perinatal predictors of the length and cost of stay.
Materials and Methods
Study design
A retrospective audit of admissions between 1/1/2012 and 31/12/2015 of infants born
after 35 weeks of gestational age with hypoglycaemia to the neonatal unit at King’s
College Hospital NHS Foundation Trust (KCH), London was performed. Infants with
a birth weight of <1.8 kg or a gestational age <34 completed weeks were routinely
admitted to the neonatal unit, irrespective of blood sugar homeostasis and were
excluded from this study. The study was registered as an audit with the Clinical
Governance Department of KCH.
On admission to the neonatal unit, the infant’s symptoms, temperature and blood
glucose levels were recorded. Subsequently, the following information was collected
from the maternal and neonatal medical notes: maternal antenatal diabetes
(yes/no), maternal antenatal hypertension (yes/no), maternal antenatal treatment
with labetalol (yes/no), maternal antenatal treatment with nifedipine (yes/no),
maternal antenatal treatment with methyldopa (yes/no), other significant maternal
medical conditions (autoimmune disease, asthma, renal and cardiac disease)
(yes/no), FGR (yes/no), maternal pyrexia >38oC (yes/no), pathological
cardiotocograph (CTG) (yes/no), delivery by caesarean section (yes/no), antibiotic
administration in labour (yes/no), Apgar score at 5 minutes <7 (yes/no),[16] male sex
(yes/no), singleton pregnancy (yes/no), gestational age at delivery and birthweight,
age of admission (hours), exclusive breastfeeding (yes/no).
Screening for gestational diabetes (GDM) was according to local protocols.
Definitions of maternal, antenatal and labour outcomes
Maternal hypertension was defined as a systolic or diastolic blood pressure
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≥140mmHg and ≥90mmHg, respectively, on two occasions four hours apart.[17]
Treatment of maternal hypertension was based on the recommendations of the
National Institute for Health and Care Excellence,[18] modified by locally derived
prediction models for the maternal response to beta-blockers.[19]Women with
previous GDM or BMI >40kg/m2underwent a 75g oral glucose tolerance test (OGTT)
at 16-20 weeks and repeated at 28 weeks if the first OGTT was normal. All other
pregnant women (regardless of other risk factors) had a random venous plasma
glucose sample taken at 26 to 28 weeks of gestation and if the level was ≥6.7mmol/l
an OGTT was undertaken. The diagnosis of maternal gestational diabetes was made
if an OGTT with a fasting glucose >5mmol/l and/or 2 hour ≥7.8mmol/l. Fetal growth
restriction was defined as a newborn with a birth weight below the third percentile or
with birth weight above the third percentile but with abnormal Doppler waveforms
and/or oligohydramnios.[20]A CTG trace was defined as pathological according to
national guidelines.[21] The birthweight z-score and percentile was calculated based
on locally derived birthweight reference ranges.[22]In order to assess the effect of
FGR and fetal macrosomia on the length and/or cost of stay, we included in the
regression models the linear and quadratic term of birthweight z-score.
Definition of hypoglycaemia and measuring devices
A blood glucose level below 2.6 mmol/L was used to define neonatal
hypoglycaemia.[23] The blood glucose measurement in the postnatal ward and in
the neonatal unit was undertaken by whole blood analysis using hand held
glucometers (Ascensia Contour blood glucose meter, Bayer Healthcare LLC, PA,
USA) which underwent a two-point calibration on a daily basis.
Management of hypoglycaemia
The management of infants at risk of hypoglycaemia in the postnatal ward and after
admission to the neonatal unit was in accordance with national guidelines.[11]
Infants required high dependency care if the intravenous dextrose concentration
required to maintain blood glucose levels exceeded 12.5% and a percutaneously
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The maternal/antenatal, labour, neonatal and admission data of the admitted infants
are presented in Table 1. One hundred and sixteen mothers had diabetes (24.5%),
94 had hypertension (19.8%), 69 had pyrexia>380C in labour (14.6%), 123 of the
infants had FGR (25.9%) and 111 (23.4%) had a pathological CTG prior to delivery
(Table 1, Figure 1). There was an overlap of pathologies in 18.8% of cases, whilst in
13.7% there was no associated pregnancy complication.
The cumulative length of stay of the admitted infants was 2,107 days, of which 960
days were in the high dependency care (HDU). Fifty-six percent of the admitted
infants were discharged by day three of stay, 85% were discharged by day 7 of stay
and 90% were discharged by day 10 of stay (Figure 2). The cumulative cost of stay
of the admitted infants was 1,316,591 GBP (329,148 GBP per year), of which
842,880 GBP related to high dependency costs.
Univariate regression analysis
The length and cost of stay were significantly associated with: history of maternal
diabetes, maternal use of Nifedipine, FGR, maternal administration of antibiotics in
labour, pathological CTG, gestational age at delivery, square ofthe birth weight
z-score, age on admission, admission blood sugar and exclusive breastfeeding
(Table 2).
There was no association between length or cost of stay and: neonatal symptoms,
admission temperature, delivery by caesarean section, maternal pyrexia in labour
>380C, Apgar score at 5 minutes<7, gender, singleton birth, maternal hypertension
or other medical conditions, maternal treatment with labetalol or methyldopa (data
not presented).
Multivariate regression analysis
Multivariate regression analysis demonstrated that greater length of admission (R2 =
0.13, p<0.0001) and cost of admission (R2 = 0.14, p<0.0001) were independently
associated with lower gestational age and blood glucose level on admission,
exclusive breastfeeding, maternal use of nifedipine, pathological intrapartum CTG,
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and small and large birthweight (table 3).
Age of admission, maternal administration of antibiotics in labour, maternal diabetes
and FGR were not independent predictors of length or cost of stay (data not
presented).
Discussion
We have demonstrated that hypoglycaemia after 35 weeks accounts for nearly one
fifth of neonatal admissions, costing approximately 1.3 million GBP over a four year
period in one tertiary NICU. Lower gestational age and admission blood glucose, low
and high z-score birthweight, maternal nifedipine and exclusive breastfeeding were
associated with longer duration of stay.
To our knowledge this is the first study to examine the association of maternal
disease and intrapartum events with the morbidity related to neonatal hypoglycaemia
as assessed by the length and cost of admission.
The prevalence of admissions for hypoglycaemia in our unit, however, was higher
than previously reported. In a recent national report, the prevalence of admissions
for hypoglycaemia was 10% for term admissions,[2] whilst in our study this was
23.3%. In our population, 86% of those with a prolonged admission had pre-existing
maternal medical disease (hypertension or diabetes), maternal antihypertensive
treatment, FGR or intrapartum complications (maternal antibiotics in labour,
pathological CTG). It is, therefore, possible that the reported 10% national rate is not
uniform across all units, but varies according to the prevalence of maternal risk
factors in local populations.
Our study highlights that the severity of neonatal hypoglycaemia may be the result of
the interplay of antenatal, intrapartum and postnatal risk factors. The maternal
disease determines the milieu of fetal development and to an extent is responsible
for the ability of the fetus to adapt to the stress of labour and early postnatal life.
Impaired maternal glucose homeostasis during pregnancy, leads to fetal
hyperglycaemia and transient hyperinsulinism.[9] A growth restricted infant will have
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impaired gluconeogenesis and low glycogen stores.[25] In our study, maternal
diabetes and FGR were not independent predictors of length and cost of stay. This is
possibly because their effect was masked by the quadratic effect of the birthweight
z-score, which showed increased length and cost of stay in low and high birthweight
z-scores.
Maternal hypertension can predispose to neonatal hypoglycaemia via multiple
mechanisms. Hypertension in pregnancy is strongly associated both with glucose
intolerance[26, 27] and placental insufficiency leading to fetal growth restriction.[27]
Furthermore, beta-blockers (antihypertensive therapy) have been associated with
interruption of glycogenolysis in the neonate due to transplacental transfer.[28]
Interestingly, in our cohort, maternal use of nifedipine rather than labetalol was
associated with prolonged stay and increased cost. The evidence for labetalol as a
cause for neonatal hypoglycaemia, however, is conflicted. Some epidemiological
studies have reported an association after controlling a small number of confounders
[10] whilst others argue that it is the fetal growth restriction, secondary to the
placental insufficiency, which causes the need for treatment and is responsible for
the neonatal hypoglycaemia.[15] Our results showing that nifedipine was associated
with longer stay and higher cost likely reflects our practice in the choice of
antihypertensive agents in pregnancy. We have previously developed a prediction
model for the response to labetalol treatment in pregnancy by using maternal
demographic and central haemodynamic data.[29] Women with low cardiac
output-high resistance are more likely to respond to a vasodilator, such as nifedipine.
Such pregnancies, are associated with established or impending fetal growth
restriction as the vasoconstriction is a compensatory mechanism for the reduced
intravascular space.[30, 31] It is therefore, likely that in our multivariate model
Nifedipine is a proxy for fetal growth restriction.
The increased risk of hypoglycaemia in late preterm infants is the result of immature
hepatic glycogenolysis and gluconeogenesis and limited enteral intake due to
gastrointestinal immaturity and poor suck–swallow coordination.[32] In agreement
with the above, our study identified low gestational age as an independent predictor
JU
ST
 AC
CE
PT
ED
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 08
:24
 27
 O
cto
be
r 2
01
7 
of admission for hypoglycaemia in infants more than 35 weeks of gestation. In our
study, exclusive breastfeeding was also identified as an independent predictor of
admission for neonatal hypoglycaemia. Early breastfeeding support increases the
likelihood of successful breastfeeding and milk production. For both public health
and economic benefit, i.e. promotion of successful breastfeeding and avoidance of
neonatal admissions, it could be argued that focusing of intensive early support for
breastfeeding in this high risk group should be prioritised.[33]
We acknowledge as a limitation that this was a retrospective study that focused on
the characteristics of the admitted infants and did not explore that management in
the postnatal ward. Nevertheless, our study group represents the most severe end of
the spectrum of hypoglycaemia with regard to morbidity and cost.
In conclusion, hypoglycaemia after 35 weeks of gestation accounted for nearly a fifth
of neonatal admissions in our population. Lower gestational age and admission
blood glucose, low and high z-score birthweight, maternal nifedipine and exclusive
breastfeeding are associated with longer duration and higher cost of stay.
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Legend to figures
Figure 1: Venn diagram demonstrating the overlapping of maternal diabetes,
hypertension, fetal growth restriction and pathological intrapartum cardiotocograph in
our cohort.
Figure 2: Histogram of days of stay in our cohort. The vertical dashed lines
demonstrate the percentage of infants discharged by day 3 and 10 of admission.
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Table 1: Antenatal, labour and neonatal characteristics of the admitted infants
(N=474)
Data presented as Mean (standard deviation) and median (interquartile range) for
normally and not normally distributed data, respectively.
Antenatal, n (%) Maternal diabetes 116 (24.5)
Fetal growth restriction 123 (25.9)
Maternal hypertension 94 (19.8)
Treatment with labetalol 59 (12.4)
Treatment with nifedipine 29 (6.1)
Treatment with methyldopa 14 (2.9)
Labour, n (%) Maternal pyrexia > 38 oC 127 (26.8)
Pathological cardiotocograph 111 (23.4)
Apgar at 5 minutes < 7 3 (0.6)
Delivery by CS 264 (55.7)
Neonatal Female gender, n (%) 226 (47.7)
Singleton birth, n (%) 392 (82.7)
Gestational age (weeks) 38.1 (36.7-39.3)
Birthweight centile 31.4 (5.4–68.9)
Birthweight z score -0.52 (1.69)
Birthweight < 3rd centile, n (%) 99 (20.9)
Birthweight < 10th centile, n (%) 158 (33.3)
Birthweight > 90th centile, n (%) 68 (14.3)
Birthweight > 97th centile, n (%) 44 (9.3)
Admission Age on admission (hours) 9.0 (6.0-15.0)
Blood sugar (mmol/L) 2.1 (1.7-2.4)
Temperature (oC) 36.6 (0.4)
Exclusive bottle feeding, n (%) 54 (11.4)
Symptomatic on admission, n (%) 122 (25.7)
Total days of stay 3.0 (2.0-5.0)
Days of stay in High Dependency Unit 1.0 (0.0-2.0)
Days of stay in Special Care baby unit 3.0 (2.0-3.0)JU
ST
 AC
CE
PT
ED
D
ow
nl
oa
de
d 
by
 [K
ing
's 
Co
lle
ge
 L
on
do
n]
 at
 08
:24
 27
 O
cto
be
r 2
01
7 
Table 2: Significant univariate predictors of length and cost of stay
Length of stay (days) Cost of stay (GBP)
R-square p-value R-square p-value
Admission blood sugar
(mmol/L)
0.05 <0.0001 0.05 <0.0001
Age on admission (hours) 0.03 <0.0001 0.04 <0.0001
Birthweight z-score square 0.04 0.03 0.04 0.03
Gest. age at delivery (weeks) 0.01 0.01 0.01 0.005
Exclusive breastfeeding 0.01 0.01 0.01 0.005
Pathological CTG 0.01 0.01 0.01 0.01
Antibiotics in labour 0.04 <0.0001 0.04 <0.0001
Maternal diabetes 0.007 0.03 0.008 0.03
Maternal use of Nifedipine 0.02 0.002 0.02 0.002
Fetal growth restriction 0.01 0.004 0.01 0.004
Table 3: Multivariate regression analysis for log-length and log-cost of stay
Length of stay (log-days) Cost of stay (log-GBP)
Coefficient -
beta
Confidence
intervals
P
value
Coefficient -
beta
Confidence
intervals
P
value
Gestational age -0.024 -0.042 to
-0.006
0.008 -0.035 -0.057 to
-0.012
0.003
Blood Glucose -0.121 -0.175 to
-0.068
<0.0001-0.151 -0.219 to
-0.083
<0.0001
Exclusive breast
feeding
0.097 0.004 –
0.191
0.04 0.153 0.034 –
0.272
0.01
Nifedipine 0.181 0.050 – 0.007 0.230 0.064 – 0.007
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0.312 0.396
Pathological CTG 0.097 0.026 –
0.168
0.007 0.134 0.043 –
0.224
0.004
Birth weight
z-score
-0.016 -0.036 –
0.004
0.11 -0.019 -0.045 –
0.007
0.15
Birth weight
z-score square
0.008 0.001 –
0.016
0.03 0.011 0.001 –
0.020
0.03
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